Health and Healthcare

Amgen : AMGN

All Amgen Articles

701 Articles

Chris Lange | Aug 25, 2016 at 8:40 AM EDT

Short Sellers Increase Bets in Major Biotechs

The August 15 short interest data have been compared with the previous report, and short interest moves were mixed across…

Chris Lange | Aug 10, 2016 at 8:50 AM EDT

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the July 29 settlement date and short interest decreased across these selected biotech…

Jon C. Ogg | Aug 2, 2016 at 12:35 PM EDT

Why Advaxis Shares Could More Than Double, Even After the Amgen Deal

According to one analyst, Advaxis shares could still easily more than double, even after news broke that biotech giant Amgen…

Lee Jackson | Aug 1, 2016 at 9:25 AM EDT

RBC Says Buy Big Biotechs Now for Possible Big 2016 Gains

Finally, concerns about biotech seem to be waning. An RBC research report notes that at the recent political conventions there…

Chris Lange | Jul 27, 2016 at 11:50 AM EDT

What to Look for in Amgen Earnings

Amgen is expected to report its second-quarter financial results after the markets close on Wednesday. Will it go the same…

Chris Lange | Jul 27, 2016 at 7:50 AM EDT

Major Biotechs See Increased Short Interest Bets

The short interest data are out for the July 15 settlement date. Short interest increased across many of these selected…

Chris Lange | Jul 24, 2016 at 10:12 AM EDT

10 Must-See Earnings for the Coming Week

24/7 Wall St. has put together a preview of Alphabet, Amazon.com, Facebook and some of the other major companies reporting…

Chris Lange | Jul 13, 2016 at 8:10 AM EDT

Short Sellers Become More Selective on Major Biotechs

The June 30 short interest data have been compared with the previous report, and short interest moves were mixed in…

Chris Lange | Jul 12, 2016 at 10:10 AM EDT

Biotechs With Drug Pipelines Closest to Zero Valuation

Credit Suisse has taken a look at which biotech companies in its coverage have the least credit given to pipeline…

Jon C. Ogg | Jun 28, 2016 at 12:01 PM EDT

5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero

[cnxvideo id=”655353″ placement=”ros”]Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently…

Chris Lange | Jun 27, 2016 at 7:55 AM EDT

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the June 15 settlement date. Biotech companies are considered a riskier group of…

Chris Lange | Jun 10, 2016 at 8:10 AM EDT

Short Sellers Become More Selective on Major Biotechs

The May 31 short interest data have been compared with the previous report, and short interest moves were mixed in…

Chris Lange | May 25, 2016 at 8:20 AM EDT

Short Sellers Grow More Selective on Major Biotechs

The May 13 short interest data have been compared with the previous report, and short interest moves were mixed in…

Chris Lange | May 11, 2016 at 8:15 AM EDT

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these…

Paul Ausick | May 7, 2016 at 12:30 PM EDT

Analysts Adjust Predictions on Medivation Buyout Price

One time when missing earnings estimates doesn't matter much is when there is bidding war for the company. That's the…

1 … 21 22 23 24 25 … 47

Amgen : AMGN

All Amgen Articles

Short Sellers Increase Bets in Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Why Advaxis Shares Could More Than Double, Even After the Amgen Deal

RBC Says Buy Big Biotechs Now for Possible Big 2016 Gains

What to Look for in Amgen Earnings

Major Biotechs See Increased Short Interest Bets

10 Must-See Earnings for the Coming Week

Short Sellers Become More Selective on Major Biotechs

Biotechs With Drug Pipelines Closest to Zero Valuation

5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero

Short Sellers Run for Cover From Major Biotechs

Short Sellers Become More Selective on Major Biotechs

Short Sellers Grow More Selective on Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Analysts Adjust Predictions on Medivation Buyout Price

The $2,400 Widow’s Benefit Myth: Why Claiming Early Doesn’t Cap What a Widow Receives

1 Plain-As-Day Dividend King to Buy on the Dip That Has Hiked Its Payout for 70 Consecutive Years

Forget SCHD: This Monthly Dividend Grower Out-Returned It by 38% Over the Last Decade

The $2,400 Widow's Benefit Myth: Why Claiming Early Doesn't Cap What a Widow Receives

Claimed Social Security at 62? Here's Why Your Monthly Benefits Could Still Increase

The $2,400 Widow’s Benefit Myth: Why Claiming Early Doesn’t Cap What a Widow Receives

1 Plain-As-Day Dividend King to Buy on the Dip That Has Hiked Its Payout for 70 Consecutive Years

Amgen : AMGN

All Amgen Articles

Short Sellers Increase Bets in Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Why Advaxis Shares Could More Than Double, Even After the Amgen Deal

RBC Says Buy Big Biotechs Now for Possible Big 2016 Gains

What to Look for in Amgen Earnings

Major Biotechs See Increased Short Interest Bets

10 Must-See Earnings for the Coming Week

Short Sellers Become More Selective on Major Biotechs

Biotechs With Drug Pipelines Closest to Zero Valuation

5 Top Biotechs Where Future Multi-Billion Dollar Drug Pipelines are Valued Almost at Zero

Short Sellers Run for Cover From Major Biotechs

Short Sellers Become More Selective on Major Biotechs

Short Sellers Grow More Selective on Major Biotechs

Short Sellers Run for Cover From Major Biotechs

Analysts Adjust Predictions on Medivation Buyout Price

The $2,400 Widow’s Benefit Myth: Why Claiming Early Doesn’t Cap What a Widow Receives

1 Plain-As-Day Dividend King to Buy on the Dip That Has Hiked Its Payout for 70 Consecutive Years

Forget SCHD: This Monthly Dividend Grower Out-Returned It by 38% Over the Last Decade

Featured Reads

The $2,400 Widow's Benefit Myth: Why Claiming Early Doesn't Cap What a Widow Receives

Claimed Social Security at 62? Here's Why Your Monthly Benefits Could Still Increase